TY - JOUR AU - Drew, Simon C. PY - 2017 M3 - Review TI - The Case for Abandoning Therapeutic Chelation of Copper Ions in Alzheimer's Disease JO - Frontiers in Neuroscience UR - https://www.frontiersin.org/articles/10.3389/fnins.2017.00317 VL - 11 SN - 1662-453X N2 - The “therapeutic chelation” approach to treating Alzheimer's disease (AD) evolved from the metals hypothesis, with the premise that small molecules can be designed to prevent transition metal-induced amyloid deposition and oxidative stress within the AD brain. Over more than 20 years, countless in vitro studies have been devoted to characterizing metal binding, its effect on Aβ aggregation, ROS production, and in vitro toxicity. Despite a lack of evidence for any clinical benefit, the conjecture that therapeutic chelation is an effective approach for treating AD remains widespread. Here, the author plays the devil's advocate, questioning the experimental evidence, the dogma, and the value of therapeutic chelation, with a major focus on copper ions. ER -